Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
DUBLIN, Aug. 2, 2021 -- (Healthcare Sales & Marketing Network) -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, inves... Biopharmaceuticals, Oncology, FDA Alkermes, nemvaleukin, mucosal melanoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Food and Drug Administration (FDA) | Marketing | Melanoma | Pharmaceuticals | Skin Cancer